Glucose and cholesterol elevations during thiazide therapy: intention-to-treat versus actual on-therapy experience (Q41681669)

7 October 2017

Glucose and cholesterol elevations during thiazide therapy: intention-to-treat versus actual on-therapy experience (English)

1 reference

7 October 2017

Elliott WJ

1

1 reference

PubMed ID

7653486

7 October 2017

language of work or name

English

0 references

publication date

1 September 1995

1 reference

American Journal of Medicine

7 October 2017

1 reference

7 October 2017

99

1 reference

7 October 2017

3

1 reference

7 October 2017

261-269

1 reference

Impairment of glucose tolerance produced by diuretics and other drugs

7 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

How dangerous are diuretics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Metabolic considerations in the choice of therapy for the patient with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration-National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Treatment of mild hypertension: a five year controlled drug trial. The Oslo study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Veterans Administration Cooperative Study Group on Antihypertensive Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Effect of diuretic therapy on glucose tolerance in hypertensive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Do antihypertensive drugs precipitate diabetes in predisposed men?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

New drugs for the treatment of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Increase in serum-lipids during treatment of hypertension with chlorthalidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Effects of antihypertensive therapy on plasma lipids and lipoproteins in the multiple risk factor intervention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Drug-induced disorders of glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Examination of the evidence from six hypertension intervention trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

How bad are diuretic-induced hypokalemia and hypercholesterolemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

An assault on old friends: thiazide diuretics under siege.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Diuretics and cardiovascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Current hypertension management: separating fact from fiction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Blood pressure, stroke, and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

A meta-analysis of outcome trials in elderly hypertensives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Management of raised blood pressure in New Zealand: a discussion document

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Applying survival methodology to adverse experience occurrences in controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

A Markovian model for comparing incidences of side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Metabolic effects of a change in antihypertensive treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Effects of reduction in dose and discontinuation of hydrochlorothiazide in patients with controlled essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Beneficial effects from systematic dosage reduction of the diuretic, chlorthalidone: a randomized study within a clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Risk factor changes after cessation of intervention in the Multiple Risk Factor Intervention Trial. The MRFIT Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Blood pressure management: individualized treatment based on absolute risk and the potential for benefit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

The appropriate goals of antihypertensive therapy: neither too much nor too little

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Initial treatment of adult patients with essential hypertension: I. Why conventional stepped-care therapy of hypertension is still indicated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

Effects of diuretic drugs on the lipid profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980158-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)80158-2

1 reference

7 October 2017

1 reference

PubMed ID

7653486